Get the Stockscreener App
16.69
0.36%
0.08
Corbus Pharmaceuticals Holdings Inc stock is traded at $16.69, with a volume of 238.46K.
It is up +0.36% in the last 24 hours and down -9.45% over the past month.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
See More
Previous Close:
$16.61
Open:
$16.62
24h Volume:
238.46K
Relative Volume:
0.37
Market Cap:
$205.47M
Revenue:
$1.54M
Net Income/Loss:
$-38.70M
P/E Ratio:
-1.5173
EPS:
-11
Net Cash Flow:
$-36.86M
1W Performance:
-10.33%
1M Performance:
-9.45%
6M Performance:
-62.96%
1Y Performance:
+261.61%
1-Day Range:
$16.15
$16.95
1-Week Range:
$16.15
$18.89
52-Week Range:
$4.00
$61.90
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Company Profile
Name
Corbus Pharmaceuticals Holdings Inc
Sector
Industry
Phone
617-963-0103
Address
500 RIVER RIDGE DRIVE, NORWOOD, MA
Compare CRBP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| CRBP | 16.66 | 205.47M | 1.54M | -38.70M | -36.86M | -11.00 |
| VRTX | 466.97 | 119.83B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 759.96 | 83.28B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 564.96 | 33.74B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 231.31 | 30.38B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.40 | 24.08B | 3.30B | -501.07M | 1.03B | 11.54 |
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-08-20 | Downgrade | BTIG Research | Buy → Neutral |
| Sep-08-20 | Downgrade | Jefferies | Buy → Hold |
| Sep-08-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-08-20 | Downgrade | ROTH Capital | Buy → Neutral |
| Jul-07-20 | Initiated | ROTH Capital | Buy |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| Mar-26-20 | Initiated | Nomura | Buy |
| Apr-05-19 | Initiated | Jefferies | Buy |
| Mar-20-19 | Initiated | Oppenheimer | Outperform |
| Jan-11-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Dec-26-18 | Initiated | H.C. Wainwright | Buy |
| Dec-07-18 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-18 | Initiated | B. Riley FBR | Buy |
| Jan-19-18 | Initiated | Raymond James | Outperform |
| Dec-14-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Nov-08-17 | Reiterated | Noble Financial | Buy |
| Sep-29-17 | Resumed | Noble Financial | Buy |
| Mar-30-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Nov-15-16 | Reiterated | JMP Securities | Mkt Outperform |
| Nov-11-16 | Reiterated | Noble Financial | Buy |
View All
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Latest News
(CRBP) Investment Report - Stock Traders Daily
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Short Interest Update - MarketBeat
Corbus Pharmaceuticals Holdings Inc. stock underperforms Friday when compared to competitors - MarketWatch
OrbiMed Advisors LLC Acquires New Stake in Corbus Pharmaceuticals Holdings Inc - GuruFocus.com
TANG CAPITAL MANAGEMENT LLC Acquires New Stake in Corbus Pharmac - GuruFocus.com
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Corbus Pharmaceuticals to Present at the Jefferies London Healthcare Conference - GlobeNewswire
Corbus Pharmaceuticals to Present at Jefferies London Healthcare Conference | CRBP Stock News - StockTitan
Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
Brokers Set Expectations for CRBP Q1 Earnings - MarketBeat
Corbus Pharmaceuticals' Sell-Off: Speculative Entry Price In Oncology And Obesity Therapies - Seeking Alpha
We're Not Very Worried About Corbus Pharmaceuticals Holdings' (NASDAQ:CRBP) Cash Burn Rate - Yahoo Finance
Corbus Pharmaceuticals Holdings Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
Corbus Pharmaceuticals Reports Q3 2024 Financials and Updates - TipRanks
Corbus Pharmaceuticals: Q3 Earnings Snapshot - CT Insider
Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Reports 3rd Quarter 2024 Financial Results and Provides a Corporate Update - GlobeNewswire
Corbus Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
(CRBP) On The My Stocks Page - Stock Traders Daily
Vanguard Group Inc's Strategic Acquisition in Corbus Pharmaceuti - GuruFocus.com
Corbus Pharmaceuticals' (CRBP) Outperform Rating Reaffirmed at Wedbush - MarketBeat
Corbus Pharmaceuticals Presents New CRB-913 Pre-Clinical Data At Obesity Week 2024 - The Manila Times
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Receives $65.86 Consensus PT from Analysts - Defense World
Short Interest in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Grows By 5.8% - MarketBeat
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Receives $65.86 Consensus Price Target from Brokerages - MarketBeat
Corbus Pharmaceuticals to Present at the Guggenheim Securities Healthcare Innovation Conference - The Manila Times
Corbus Pharmaceuticals Holdings Inc. stock rises Monday, still underperforms market - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock rises Thursday, still underperforms market - MarketWatch
Up 174% in 2024, Is It Too Late to Buy This Breakout Biotech Stock? - Inkl
Up 174% In 2024, Is It Too Late To Buy This Breakout Biotech Stock? - Barchart
Corbus Pharmaceuticals (NASDAQ:CRBP) Stock Price Crosses Below 50 Day Moving AverageWhat's Next? - MarketBeat
Oppenheimer maintains steady target on Corbus Pharmaceuticals By Investing.com - Investing.com UK
Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701) - GlobeNewswire
Millennium Management LLC Adjusts Stake in Corbus Pharmaceuticals - GuruFocus.com
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.39%
0.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):